Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial of a personalized antisense oligonucleotide targeting ATN1 mutation for Dentatorubral-Pallidoluysian Atrophy, currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dentatorubral-pallidoluysian Atrophy

Drugs mentioned

• ATN1-targeted antisense oligonucleotide

Snippet

Sponsor: n-Lorem Foundation | Conditions: Dentatorubral-Pallidoluysian Atrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING